The 23rd annual BIO-Europe event also broke records for the number of one-to-one partnering meetings-nearly 24,200, up 9% from 2016.
Carlsbad, CA and Berlin, Germany – November 14, 2017: BIO-Europe® 2017, the largest European annual global life science partnering event, made Berlin, Germany the center of drug development partnering November 6–8. An all-time high of over 4,000 executives from the life science/drug development industry attended.
The 23rd annual BIO-Europe event also broke records for the number of one-to-one partnering meetings—nearly 24,200, up 9% from 2016. CEOs and decision makers from 2,199 companies and 61 countries discussed asset deals and strategic collaborations. There were 5,142 licensing opportunities on offer, 152 company presentations and 106 exhibitors.
This year’s conference was also part of Berlin Science Week 2017, an international gathering that brought people from the world’s most innovative scientific institutions together in Berlin.
“Partnering is a critical ingredient in successful strategic planning by companies spanning all aspects of drug development, so the incredible success of BIO-Europe bodes well for the future of healthcare. The event attracts and facilitates partnering among not only the traditional pharma, biotech and academia but also the new players in the spectrum—startup biotech companies, innovators in cell and gene therapy and digital medicine, and many more,” said Anna Chrisman, Managing Director, EBD Group and KNect365 Life Sciences. “Berlin was an outstanding host as one of the leading life sciences and healthcare industries centers in the world.”
“BIO-Europe 2017 was a unique chance for the city of Berlin, the Cluster HealthCapital and the outstanding scientific institutes and companies from Berlin. And yes, we made it! In a BIO-Europe full of records we were able to present all advantages of our vibrant city to an international Life Science community. We are looking forward to welcoming this show back to Berlin soon,” said Dr. Kai Bindseil, Cluster Manager HealthCapital Berlin-Brandenburg at Berlin Partner for Business and Technology.
Highlights included a Startup Slam pitching competition offering emerging entrepreneurs a chance to pitch their company to potential partners and investors. Once again sponsored by Johnson & Johnson Innovation, the event was won by Thomas de Vlaam, CEO and founder of Amylon Therapeutics, a startup company that targets Central Nervous System (CNS) disorders through an ultra-genetics approach.
Following up on the valuable contacts and deals made in Berlin, the life science industry is getting ready for BIO-Europe Spring® in Amsterdam, The Netherlands, March 12–14, 2018, hosted by Health~Holland. This springtime counterpart of BIO-Europe annually attracts over 2,500 attendees.
“Health~Holland is honored to welcome BIO-Europe Spring 2018 to the Netherlands, a country known for partnerships, innovation and collaboration. Let’s meet, connect and join forces during this key partnering conference in Amsterdam,” said Hans Schikan, biotech entrepreneur and Top Team member of Top Sector Life Sciences & Health.
Planning is also underway for BIO-Europe 2018 in Copenhagen, Denmark November 5–7, 2018 in partnership with Copenhagen Capacity and Invest in Skåne.
